Sutent Pancreatic Tumor Study Shows Regulatory Pitfalls Of Stopping Early
Executive Summary
Pfizer’s development of Sutent (sunitinib) for treatment of pancreatic tumors shows the potential pitfalls sponsors face when they decide to terminate clinical trials early due to positive results.
You may also be interested in...
Data At ASCO From J&J Zytiga Trial’s Early End = Intel For Medivation’s MDV3100 Program
Details from the COU-302 trial of Johnson & Johnson’s Zytiga, stopped early for efficacy in March, were released at the American Society of Clinical Oncology meeting, revealing to Medivation/Astellas insights on how to tweak their ongoing registrational trial for enzalutamide (MDV3100) in the pre-chemo prostate cancer space.
Will China's Enlarged Medical Insurance System Cover More Oncology Treatments?
SHANGHAI - Although China's pharmaceutical market slowed down in the first quarter of 2011 due to price cuts and policy headwinds, it still grew at 14.5% compared to the same period last year, according to data from investment brokerage Citi. Growth largely was driven by increasing medical expenses in the world second largest economy, and in particular was fueled by China's second and third-tier cities, away from the coast, which saw first quarter prescription drug growth rates between 20-30% year over year
Sutent Cleared For Pancreatic Tumors, But With Caveat On Efficacy
FDA approves Pfizer's sunitinib with labeling that states the magnitude of progression-free survival benefit seen in the pivotal study may have been overestimated due to the trial's early termination.